| abstract |
The present invention relates to new compounds, particularly novel pyridinone derivatives according to formula (I) wherein the radicals are as defined in the invention and the claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with dysfunction and glutamate and diseases in which the subtype mGluR2 of metabotropic receptors is involved. Particularly, such disorders of the central nervous system are diseases selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and methods for preparing such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved. |